|Bid||0.00 x 0|
|Ask||53.24 x 100|
|Day's range||50.47 - 52.10|
|52-week range||27.79 - 52.56|
|PE ratio (TTM)||47.31|
|Earnings date||2 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||52.89|
On a per-share basis, the Audubon, Pennsylvania-based company said it had net income of 25 cents. Earnings, adjusted for pretax expenses and non-recurring costs, came to 38 cents per share. The results ...
Globus Medical (GMED) classifies its products into innovative fusion products and disruptive technology products. Sales of innovative fusion products rose to $80.2 million in 3Q17 compared to $68.4 million in 3Q16. The increase was attributable to the increase from Alphatec’s international sales.
Globus Medical (GMED) recently launched a robotic surgical navigation device. Since its inception in 2003, Globus Medical has launched more than 180 products. Globus Medical acquired KB Medical, a Switzerland-based robotic developer, in June 2017.
Globus Medical (GMED) is a medical device company with a focus on designing, developing, and commercializing musculoskeletal solutions. Globus Medical’s sales force is comprised of direct sales representatives and distributor sales representatives employed by exclusive independent distributors. Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating.
MiMedx Group (MDXG) operates in the regenerative biomaterials segment. MiMedx is a leading global supplier of amniotic tissue products and has supplied over a million allografts in wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.
A new spine surgery robot has arrived on the scene to challenge Mazor's current dominance.
Globus Medical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Globus Medical (GMED) saw its shares rise nearly 8% on the day after the company reported year-over-year growth in third-quarter earnings and revenues.
Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.
The musculoskeletal-implant maker eyes its new Excelsius GPS robotic surgical system for future growth.
On a per-share basis, the Audubon, Pennsylvania-based company said it had profit of 26 cents. Earnings, adjusted for one-time gains and costs, came to 30 cents per share. The results met Wall Street expectations. ...